Manchest onv entre 3r & ept - ELRIG · Thr kly D Williams, Universit er Nov edic oxicity 10.30 –...

www.elrig.org

Drug Discovery 2013Manchester Central Convention Centre

3rd & 4th September 2013

In collaboration with

Welcome WordsWe wish you a warm welcome to the 7th annual Drug Discovery conference,organized by ELRIG (European Laboratory Robotics Interest Group) andsupported by SLAS (Society for Laboratory Automation and Screening).

ELRIG Drug Discovery has become the largest free-to-attend drugdiscovery conference in Europe, and includes the leading drug discoverytechnology vendor exhibition in the UK. We are excited to introduce whatwe think is one of the strongest line-ups of speakers, posters andexhibitors, from around Europe, that ELRIG Drug Discovery has everhosted. With so many eminent academic and industry scientistspresenting, Drug Discovery has deservedly become a major meeting placefor scientists from pharma, biotech and academia who are engaged in thechallenges of preclinical drug discovery.

We are delighted to welcome you, as a delegate, exhibitor, posterpresenter or speaker (or perhaps as several of the above!) to ManchesterCentral exhibition centre. We are located in the heart of Manchester,which has a fantastic heritage of innovation in science and technology. Wehope you will take the time to experience this great city during your visit.

Over the next two days, a superb range of world-class Speakers will bepresenting in eight Science Tracks. We have selected these tracks to coverkey current areas for Drug Discovery – from the advancing roles ofMacromolecules in drug discovery and as therapeutics, through thecurrent and future directions of Oncology research, to the exciting futurethat complex Primary and Stem Cell cultures will enable. This latter topicwill also feature prominently within our Plenary Lecture, given this year byRuth McKernan (Pfizer Neusentis). Ruth has been a passionate advocate ofstem cells as enabling tools for drug discovery for many years and we aredelighted to welcome her to Drug Discovery 2013. In vitro Safety,toxicology and drug metabolism assays are also addressed this year, asthese are key to delivering safe, efficacious and well tolerated medicines.We will once again look forward to the tracks covering Advances in AssayDevelopment and Screening, and chemical and biological SampleManagement. We are delighted to introduce a new track this year onTarget Validation and Biomarker identification - improvements in this areawill critically underpin our desire to improve success in translating in vitrotargets to success in the clinic.

Drug Discovery 2013 will end with a debate on the Future Landscapeof European Drug Discovery. In this, experts from across the key sectors offunding, academia and industry will discuss their ideas on new modelsand approaches that can ensure a vigorous, robust and successful drugdiscovery landscape in Europe.

About ELRIGWelcome to ELRIG’s Drug Discovery 2013!

ELRIG is a voluntary organisation, acting as the hub of thedrug discovery community in the UK and parts of Europe.We are dedicated to all aspects of technology neededwithin the drug discovery process, with a special emphasis

on the use of automation, robotics, instrumentation and biologicalsolutions in the life science research and drug discovery productionlaboratory.

With over 7000 members in our community, which consists of scientists,researchers, engineers, developers and business-people, all of whomhave an interest in drug discovery and the associated technologicaldevelopments in this field, we are delighted to once again to host andrun the premier drug discovery conference and exhibition in Europe,Drug Discovery 2013.

The meeting is a 48 hour festival of all that is new and relevant in ourindustry. From the latest technology presentations from innovativescientists, to workshops helping our community members to improvetheir careers and of course not forgetting the challenging Dragon’s Den!If it is connected to drug discovery, you will find it in the ManchesterCentral Convention Centre, over the next 2 days.

As a voluntary organisation, there are many people who have given theirtime to make this event happen, I would like to thank all of them for theirsupport and help in making this the drug discovery event of the year.My especial thanks to the Scientific Committee, led by Peter Simpsonand Del Trezise, for the fantastic programme that they have put together,all the vendors who make this event possible and the ELRIG committeemembers for their support throughout the year.

I also would like to thank you for your attendance and continuingsupport for ELRIG and all it stands for.

Have a wonderful meeting!

Sanj KumarChairman ELRIG

About SLASThe Society for Laboratory Automation and Screening (SLAS) is aninternational community of more than 10,000 individual scientists,engineers, researchers, technologists and others from academic,government and commercial laboratories. SLAS provides forums foreducation and information exchange to encourage the study of andadvance laboratory science and technology for the drug discovery,agrochemical, biotechnology, chemical, clinical diagnostic, consumerproduct, energy, food, forensic, pharmaceutical, security and otherindustries.

SLAS works hard to deliver tangible educational programs and servicesto its members. Professionals at all levels who actively invest their timeand energy in their SLAS memberships often experience immeasurablereturns on their investments. Those who contribute as volunteers andcommittee members enjoy even greater advantages.

Scientific education, practical information, professional career- building,and valuable networking opportunities can open many doors topersonal and professional success. Acknowledge your role in the uniquefield of laboratory science and technology. Join the only international,non-profit society devoted exclusively to your best interests. Join SLAStoday at www.slas.org.

The meeting features the most extensive poster session Drug Discoveryhas held to date – do take the time to peruse these posters and question theposter presenters. To whet your appetite, there will be poster taster talksincorporated in each session, also several poster competitions.

Drug Discovery 2013 is proud to host an extensive exhibition for DrugDiscovery products and services, where you can find new and excitingtechnologies to enable your own discovery success. This exhibitionincorporates a thriving Innovation Zone for new companies promoting newtechnologies to the market.

In developing the program for this meeting, ELRIG is placed at the centreof the European Drug Discovery community, with the objective of bringingtogether scientists from across the field, whether they are based in academia,the pharmaceutical, or biotech industries. We hope the opportunity to mixand mingle in the 8 Science Tracks, exhibition hall, poster area, and drinksreception will enable you to meet colleagues and collaborators old and newand to establish new partnerships that will advance the science of drugdiscovery.

As in past years, registration and attendance at the show is FREE – we canonly do this because of the support of our sponsors and exhibitors. We are verygrateful to the army of volunteers who make ELRIG Drug Discovery a success –from Session chairs, to Poster Session organisation, conference set-up andmembers of ELRIG committee. Also we would like to acknowledge thededicated service of Terry Wood as outgoing ELRIG chairman and welcomeSanj Kumar who has taken over as Chairman this year.

This is our first year organizing the program for this conference, steppinginto the shoes of Steve Rees and Adrian Kinkaid who have been key to thedelivery of many years of great ELRIG Drug Discovery conferences. As theProgram Chairs for the 2013 show, we would like to thank everyone who hascontributed to past Drug Discovery events and to helping us with theorganisation of this year’s program - especially Jackie Howard and DermotBoylan of ELRIG without whom these meetings simply would not happen.We hope you will find it a stimulating and enjoyable event that you willreturn to in future years.

Drug Discovery 2014 will be in Manchester on 2nd & 3rd September2014 - so please make a date in your diary!

Best regards,

Peter Simpson & Del TreziseProgram Chairs, ELRIG Drug Discovery 2013

Closing Debate in Charter 1

The changing Landscape of Drug Discovery in Europe

Key topics:• Will the future of European drug discovery be led by

academia rather than Pharma?• Can Pharma work together effectively in a

pre-competitive manner? & is this a good thing?• How can academics best work with Pharma to benefit

both sides?• How can we find the best target ideas across Europe,

and turn them into new medicines?• Who should fund drug discovery? Pharma,

government, charities?• What will/should the European drug discovery sector

look like in 5 years' time?

Panel: Peter Simpson, Kevin Johnson, Peter Nussbaumer,Chas Bountra

Poster Awards

Keynote Speaker

ELRIG PresentsThe SLAS Young Scientist Award

Students, graduates and post-docs are welcome to compete for the SLAS Young Scientist Award at theELRIG Drug Discovery 2013 Annual Conference and Exhibition, 3rd & 4th September 2013.

Students, graduates and post-docs are welcome to compete for the SLAS Young Scientist Award at the ELRIG Drug Discovery 2013 AnnualConference and Exhibition,

The winner will be invited to present and participate in the Student Poster Competition at the 3rd Annual SLAS Conference and Exhibition,January 18-22, 2014 at the San Diego Convention Center in San Diego, California, USA. SLAS Young Scientist Award winners receive a $500 cashprize, round-trip coach airfare, shared hotel accommodations and conference registration for SLAS2014.

The winner will be invited to present and participate in the Student Poster Competition at the 3rd Annual SLAS Conference and Exhibition,January 18-22, 2014 at the San Diego Convention Center in San Diego, California, USA. SLAS Young Scientist Award winners receive a

$500 cash prize, roundtrip coach airfare, shared hotel accommodations and conference registration for SLAS2014.

The SLAS Young Scientist Award program is a global initiative in partnership with the following organizations:• European Laboratory Robotics Interest Group, United Kingdom• Institute of Food Technologists, United States• MipTec, Switzerland

For information regarding the ELRIG Drug Discovery 2013 SLAS Young Scientist Award,please contact Dermot Boylan, ELRIG General Manager, at [email protected].

Ruth McKernan, PfizerPractical applications of stem cell-derived cells within drug discovery

Ruth McKernan is Senior Vice President of Pfizer and ChiefScientific Officer at Pfizer ‘s Cambridge Research Unit,Neusentis. Born in Scotland, she gained her PhD at LondonUniversity’s Institute of Psychiatry studying the mechanismof action of antidepressant drugs. After two years on a

Fulbright Scholarship at the University of California in San Diego, shejoined the pharmaceutical Industry.

Ruth spent 17 years at Merck, becoming head of the MerckNeuroscience Research Centre in Harlow in the UK in 2001. She joinedPfizer in 2005 as Vice President of Biology in Sandwich. Since then shehas been head of the Research Technology Centre in Boston and in 2008she started Pfizer Regenerative Medicine, a new area of innovation forthe company. In 2010 she was additionally appointed as head of theSandwich Site. In April 2011, she formed the new Cambridge ResearchUnit, Neusentis.

She sits on the Board of Pfizer, UK, and on multiple Advisory Boardsincluding Cancer Research Technologies, She is also a member of theMedical Research Council.

Scientifically, Ruth is best known for her research in neuroscience, and isthe author of over 130 publications and 15 patents. She has also wonawards for science writing and her first book for non-scientists, Billy’s Halo,was short-listed for the 2007 MIND awards.

Cambridge Bioscience are sponsoring theWi-Fi throughout the show.

Log in details:Connect to: MCCC

then follow the instructions

Careers Zone

During the Drinks Reception - We are organising a Careers Ice BreakerRecruiters and Vendors will be encouraged to wear a - ‘I’m Hiring’ - badge.

Pick up your badge at the Careers Zone.Candidates will then be able to approach the companies to talk about their

next career move and the available Job Vacancies.

If you are looking for a job, or looking for people, where better than ELRIG to network?

George James LtdGeorge James Ltd are delighted to be supporting the ELRIG DrugDiscovery Conference which has established itself as the leading

conference covering this subject hosted in the UK. During theconference we will have specialists available to provide free

45 minute advice sessions to exhibitors and delegates.

Lunchtime Seminars Media ZoneVisit the Media Zone and talk

to the Industry Press:BioNowBPSDDNDDTDDW

EmailerGoEPR

EventfloGEN

LabmateLab Innovations

Lab NewsSelectScience

SLASSwift Analytical

Technology NetworksZymecommunications

SiLaStandardization inLab Automation

Tuesday 3rd September - 1.00 – 1.45pmIn the Exhibition Hall at the Dragons Den theatre

Abstract: The presentation and afternoon talk reports about thecreation and contents of the first set of standard specifications

developed since 2010. These specifications—named DeviceControl and Data Interface Specification, Common Command

Dictionary, and Data Capture Specification—describe howdevices are connected to a software controlling the interplay of

the devices, the command sets for various device classes, and thestructure of result data such as data generated by readers.

Jason MeredithSoftware Product Manager, Tecan.

SLASTuesday and Wednesday in Exchange 10

Day 1: 1.00 - 1.45 – Sabeth Verpoorte, University of Groningen“The potential of microfluidics to improve in-vitro

technologies for drug discovery”.

Day 2: 1.00 - 1.45 – Olivier Pierrat, University of Reading"An in vitro assay development and high throughput screenidentified monocyclic beta-lactams as mechaism-based

inhibitors of rhomboid intramembrane protease".

Langton HowarthLangton Howarth is a specialist recruitment consultancy

working within the Life Science, Diagnostic, Healthcare andConsumer Health and Beauty industries. We offer an

unparalleled quality of service and a consistent commitmenttowards our clients and candidate, and aim for nothing shortof excellence. Visit us at the Careers Zone for unbiased advice

about your future career move or current recruiting needs.

Free Careers Advice

CV Master Class

Interview Techniques

Hiring Tips

ELRIG 2013DRAGonS DEn

Join us in the Exhibition Hall at 6.30on Day 1 where you will witness ELRIG’s

answer to DRAGONS DEN...

DragonsLorenz MayrAstraZeneca

Graeme DanielsCytocentrics Bioscience GmbH

Vashu PamnaniCambsBio

Todd UptonCorning

Compere:Sanj Kumar

ELRIG Chairman

Contestants:Companies from our Industry present their

New Ideas to our Panel of Dragons

zK[ZaZOZTUwbWW

l^\{

^PX

nTPO^QP |bQ^^QPcTU^

r^_ZbcTU^

{{{{>>DD44 llTTTTVVPP** rrbbUU`̀[[^̂PPOO^̂QQ ||^̂UUOOQQbbWW

jQb`X D

jQb`X 9

jQb`X 4

sNU`[OZV^k^VZUbQP

rbZUzUOQbU`^

~h j^`[UZ`ZbUP

oQ\bUZP^QPo]]Z`^PD* 9 � 4

iS_bO^_ G#<G+<D4

zW^MbOTQP OTiU_^Q\QTNU_|bQ)nbQX

|bO^QZU\{Qb\TUP {Û

vUUTMbOZTU cTU^

h^[Z`W^ {TTQ {sTb_ < iUWTb_

~``^PPlbVS

jQb`X @

|TU`Z^Q\^ k^QMZ`^

kObZQP

iS kObZQP OT

rbZUzUOQbU`^

rZ_WbU_wTO^W

jTZWÔP

jTZWÔP

Your Invitation toSelectScience-SponsoredReception and AwardsPlease join colleagues at the Tuesday DrinksReception (5.00-7.00pm, exhibit hall), tocelebrate with SelectScience:

• Announcing the Scientists’ Choice Awards‘Best Drug Discovery Product of 2013’.

• Celebrate SelectScience’s 15 year anniversary and recent Queen’s Award honour.

Speaker ProgrammeSession 1, Day 1 – Charter 1

Manchester Central Convention Complex, UK3rd & 4th Sept 2013

9.10 – 9.15 Introductions andWelcome

Paul Whittaker, NovartisLorenz Mayr, AstraZeneca

9.15 – 10.00 Session KeynoteJoe Arron, Genentech

Non-invasive biomarkers that predict treatment benefit frombiologic therapies in asthma

10.00 – 10.30 Lorenz Mayr, AstraZeneca Strategies for Target Validation

10.30 – 11.00 COFFEE/EXHIBITION

11.00 – 11.30 Mark Carlton, Takeda Target Validation approaches in the CNS area

11.30 – 12.00 Poster Taster Session Carl Christel, Par Nordlund

12.00 – 12.30 Snapshots Aptamar Solutions

12.30 – 2.00 LUNCH/EXHIBITION/POSTER VIEWING Lunchtime workshops

2.00 – 3.00 Plenary Keynote Speaker - Charter 1Ruth McKernan, Pfizer

Practical applications of stem cell-derived cells within drug discovery

3.00 – 3.30 Jeremy Besnard, University of Dundee

Automated Design of ligands with targetedpolypharmagology

3.30 – 4.00 Jason Witherington, GSK Unravelling the therapeutic potential of Epigenetics throughthe application of Small Molecule Probe inhibitors

4.00 – 4.30 Keith Wafford, Lilly Sleep EEG as a translational biomarker and targetidentification tool

4.30 – 5.30 POSTER PRESENTATIONS Charter Foyer

5.00 – 7.00 DRINKS RECEPTION

5.30 – 6.30 SELECTSCIENCE DRUG DISCOVERY AWARDS Exhibition Hall

6.30 – 7.30 DRAGONS DEN Exhibition Hall

Target & Biomarker Identification & Validation




Leo Price, University of LeidenTodd Upton, Corning

9.15 – 10.00 Session KeynoteClemens van Blitterswijk,University of Twente

Building Tissue High Throughput

10.00 – 10.30 Yolanda Chong,Janssen Pharmaceutica

Multi-parametric high-content screening to enablecompound classification in drug discovery


11.00 – 11.30 Florian Hollfelder,University of Cambridge

Formats for High-throughput Biology in MIcrofluidicDroplets

11.30 – 12.00 Poster Taster Session Alexander McGowen, Dmitri Papkovsky

12.00 – 12.30 Todd Upton, Corning Stems cell bioprocessing: scaling up for drug discovery and the clinic




3.00 – 3.30 Chris Denning,University of Nottingham

Automation for human pluripotent stem cells: Friend or foe?

3.30 – 4.00 Stefan Braam,University of Leiden

Human stem cell derived cardiomyocytes in drug discoveryand development

4.00 – 4.30 Rob Vries, Hubrecht Institute Novel Human patient models for drug development





Advanced Cell Technologies




Barry Jones, AstraZenecaStuart Baddeley, GSK

9.15 – 10.00 Session KeynoteDennis Smith,University of Liverpool

Through a membrane, Darkly

10.00 – 10.30 Dominic Williams,University of Liverpool

Novel in vitro and in silico models for the prediction ofchemical toxicity


11.00 – 11.30 David Hay,University of Edinburgh

Developing high fidelity hepatotoxicity models frompluripotent stem cells

11.30 – 12.00 Poster Taster Session Carole Crittenden, Darren Jones

12.00 – 12.30 Snapshots Hamilton, Mimetas, Electrospinning



Practical applications of stem cell-derived cells within drugdiscovery

3.00 – 3.30 Jim Louttit, GSK Use of in silico and in vitromodels in a functionalcardiovascular hazard identification strategy

3.30 – 4.00 Dermot McGinnity,AstraZeneca

The value of DMPK assays in drug discovery anddevelopment

4.00 – 4.30 Amin Rostami,University of Manchester

Modelling and simulation: No longer an isolated activity





In Vitro DMPK & Safety Screening




Catherine Kettleborough, MRCTPhil Bland-Ward, SweetSpot Therapeutics

9.15 – 10.00 Session KeynoteKevin Johnson, Index Ventures

The inexorable rise of biologic drugs

10.00 – 10.30 John Lambert, ImmunoGen Antibody-Drug Conjugates (ADCs): The Magic BulletRealized for Cancer Treatment?


11.00 – 11.30 David Matthews, MRCT Developing drugs in the diverse world of antibodytherapeutics molecule

11.30 – 12.00 Poster Taster Session Lisa Kitching, Anass Jawhari

12.00 – 12.30 Snapshots Almac, ALS, Venomtech, TAP




3.00 – 3.30 Mark Edbrooke, GSK Oligonucleotides as novel therapeutics: where are we now?

3.30 – 4.00 Heather Fairhead, Phico Therapeutics Development of SASPject: A novel antibacterial platform technology

4.00 – 4.30 Kerry Fisher, PsiOxus ColoAd1: a self-replicating cancer vaccine





Macromolecules as Therapeutics



Innovations in Assay Development & Screening


Steven van Helden,Pivot Park Screening CentreAlan Wise, TPP Global Development

9.15 – 10.00 Session KeynoteSylviane Boucharens, BioCity Scotland

The European lead Factory; the new pan-European drugdiscovery platform

10.00 – 10.30 Huib Ovaa, NKI EU-OPENSCREEN


11.00 – 11.30 Manfred Auer, University of Edinburgh The SESMOS Screening Process: Advanced in-silicotechnology, micro-medicinal chemistry, label free detection,and single molecule resolution

11.30 – 12.00 Poster Taster Session Leif Larson, Claire McWhirter

12.00 – 12.30 Snapshots Sophion, Dotmatics, Genedata, Sirion, Tecan


2.00 – 2.30 Sheila McLoughlan, CRT Targeting Cancer Metabolism

2.30 – 3.00 Namir Hassan, Immunocore Incucyte: a novel platform for measuring cytotoxic Tlymphocyte killing

3.00 – 3.30 Helena Lindmark, AstraZeneca The challenges facing PI3 kinase in drug discovery from anin vitro assay and screening perspective

3.30 – 4.00 COFFEE BREAK

4.00 – 5.00 CLOSING PANEL DISCUSSION - CHARTER 1Peter Simpson, Kevin Johnson, PeterNussbaumer, Chas Bountra


5.00 – 5.15 CLOSE OF CONFERENCE Prize Draw in Charter 1



Science Led Sample Management – Putting the horse before the cart


Tim Peakman, UK BiobankClive Green, AstraZeneca

9.15 – 10.00 Session KeynotePaul Burton, Leicester University

Understanding the effects of variation in sample collectionand handling on the power of association studies

10.00 – 10.30 Darren Rimmer, GSK Incorporating sample collections from acquired companiesinto GSK – simple?


11.00 – 11.30 Jim Cooper, ECACC, PHE Preventing Culture Shock: Fit for PurposeCell Supply

11.30 – 12.00 Poster Taster Session Anne Laan, Jonathan Wrigley

12.00 – 12.30 Snapshots Titian


2.00 – 2.30 Ian Sinclair, AstraZeneca Identifying and managing compounds at risk of instability torelease value from chemical assets

2.30 – 3.00 Drew Hope, Kings College Challenges of biosample management in AdvancedTherapies

3.00 – 3.30 Daniel Baeschlin, Novartis Compound management at Novartis: quality, flexibility,throughput







oncology Drug Targets – Where next?


Tim Hammonds, CRTTim Perera, ITS JnJ

9.15 – 10.00 Session KeynoteMatthew Garnet, Wellcome TrustSanger Institute

Genomic Biomarkers of Drug Sensitivity in Cancer Cells

10.00 – 10.30 Owen Sansom, Beatson Institute Testing the concept of 'precision' medicine using preclinicalmouse models


11.00 – 11.30 Christian Dillon, CRT Translating oncology targets at the academia-industryinterface: challenges and opportunities in target selectionand validation

11.30 – 12.00 Poster Taster Session Frederique Hudon, Christine Daly

12.00 – 12.30 Snapshots DiscoverX, CambsBio


2.00 – 2.30 Ian Waddell, CRUK Oncology Drug discovery in an Academic Setting: Pipelineor Pipedream?

2.30 – 3.00 Pam Carroll, Janssen Pharmaceutical Raising the bar on target biology validation to increaseclinical POS

3.00 – 3.30 Graeme Smith, AstraZeneca Finding and prosecuting the right oncology target







Macromolecules as Tools for Discovery & Target Validation


John McCafferty, Cambridge UniMike Dyson, Iontas Ltd

9.15 – 10.00 Session KeynoteJohn McCafferty, Iontas Ltd

Blocking Cell Signalling with Recombinant Antibodies

10.00 – 10.30 Bruce Carrington, UCB Antibodies as Tools in Drug Discovery


11.00 – 11.30 Kate Wickson, AstraZeneca FAbRICating Crystals: Antibody assisted crystallisation tofacilitate small molecule drug discovery

11.30 – 12.00 Poster Taster Session Laura Kilpatrick, Steve Trim

12.00 – 12.30 Snapshots Almac, OcellO


2.00 – 2.30 Jean-Pierre Cabaniols, Cellectus TALE-Based molecular tools for genome engineering

2.30 – 3.00 Christian Jost, University of Zurich Engineering Growth Factor Receptor Ligands with PowerfulCellular Responses

3.00 – 3.30 Ralph Minter, MedImmune Phenotypic Screening for Therapeutic Antibodies and NovelDrug Targets





Exhibitors

Abcamwww.abcam.com

Dotmatics Limitedwww.dotmatics.com

ProQinasewww.proqinase.com

ABS Inc.www.absio.com

Eppendorf UK Ltdwww.eppendorf.co.uk

Redd&Whytewww.reddandwhyte.com

Agilent Technologieswww.agilent.com/chem

Essen BioSciencewww.essenbioscience.com

ReTiSoft Inc.www.retisoft.ca

Almacwww.almacgroup.com

Formulatrix Inc.www.formulatrix.com

Roche Diagnosticswww.roche.com

ALS Automated Lab Solutions GmbHwww.als-jena.com

Genedatawww.genedata.com

SB Drug Discoverywww.sbdrugdiscovery.com

AMSBIOwww.amsbio.com

Gilson UKwww.gilsonuk.com

Sophion Biosciencewww.sophion.com

Andrew Alliancewww.andrwalliance.com

Greiner Bio-Onewww.gbo.com

Source BioSciencewww.sourcebioscience.com

Astech Projects Ltdwww.astechprojects.co.uk

Hamamatsu Photonics UK Ltdwww.hamamatsu.co.uk

Synentec BioServices GmbHwww.synentec-bioservices.com

Aurelia Biosciencewww.aureliabio.com

Hamilton Robotics Ltdwww.hamiltonrobotics.com

TAP Biosystemswww.tapbiosystems.com

Beckman Coulter Ltdwww.beckmancoulter.com

HighRes Biosolutions Ltdwww.highresbio.com

Tecan UKwww.tecan.com

Bigneatwww.bigneat.com

IDBSwww.idbs.com

Thermo Fisher Scientificwww.perbio.com

Biowake / Ziathwww.biowake.com

InSCREENeX GmbHwww.inscreen.com

Titian Softwarewww.titian.co.uk

BMG Labtechwww.bmglabtech.com

INTEGRA Bioscienceswww.integra-biosciences.com

TTP Labtechwww.ttplabtech.com

Brooks Automation www.brooks.com/lifescience

Labcytewww.labcyte.com

Venomtech Ltdwww.venomtech.co.uk

Cambridge Biosciencewww.bioscience.co.uk

LiconicUK LTDwww.liconic.com

Zinsser Analytic GmbHwww.zinsser-analytic.net

CCS Cell Culture Servicewww.cellcultureservice.com

Life Technologieswww.lifetechnologies.com Innovation Zone:

Cellectis bioresearchwww.cellectis-bioresearch.com

Luxcel Biosciences Ltdwww.luxcel.com

SIRION BIOTECH GmbHwww.sirion-biotech.com

Cellular Dynamics Internationalwww.cellulardynamics.com

Membrane Protein Alliancewww.calixar.com/membraneproteinalliance

Cleaver Scientificwww.cleaverscientific.com

Chembridge Corporationwww.chembridge.com

Molecular Deviceswww.MolecularDevices.com

CYP Design Ltdwww.cyp-design.com

Cisbio Bioassayswww.htrf.com

Nanostring Technologieswww.nanostring.com

Genalyte Incwww.genalyte.com

Computypewww.computype.com/en-gb

Norgren Ltdwww.norgren.com

Mimetas BVwww.mimetas.com

Corning Life Scienceswww.corning.com/lifesciences

Pall-ForteBiowww.pall.com

OcellOwww.ocello.nl

Cronus Technologieswww.cronustechnologies.co.uk

Peak Analysis and Automation (PAA)www.paa-automation.com

Scitegrity Limitedwww.scitegrity.com

Cytoowww.cytoo.com

Porvair Sciences Ltdwww.porvair-sciences.com

The Aptamer Group Ltdwww.apatamersolutions.co.uk

DiscoveRxwww.discoverx.com

Promega UK Ltdwww.promega.com

The Electrospinning Company Limitedwww.electrospinning.co.uk

Founding Sponsors

Sponsors

Poster Sponsors

Media Sponsors

DD 2013 Sponsors

plastic

c

Products &

s

revolutionarym

Products &

s

www.strobotics.com.

revolutionarym



Meetings in 201411th March 2014

Research & Innovation - Impact into Cancer1 Day - 3 Sessions

Telford International Centre

2nd & 3rd September 2014Drug Discovery '142 Days - 8 Sessions

Manchester Central

November 2014Flow Cytometry & Imaging

2 DaysVenue TBC

For more information please contact:Jackie Howard: Email: [email protected] - Mobile: 07879 050 555Dermot Boylan: Email: [email protected] - Tel: 0845 017 0517

ELRIG 2014 Meetings

Manchester Central

Telford International Centre

DelegateRegistrationis FREESpeakersEvolving stable and well expressing GPCRs for structuredetermination and drug screeningAndreas Plückthun, University of Zurich

CHO genome engineering to decrease transcriptional andprotein processing bottlenecksNicolas Mermod, University of Lausanne

Systems Biology for improving production of cellular productsPedro Mendes, University of Manchester

Correct protein folding in the ER is driven through mitochondrialfunctionRandy Kaufman, Sanford-Burnham Medical Research Centre, La Jolla

Maximising recombinant protein expression through systematicgene designClaes Gustafsson, DNA 2.0, San Francisco

ExhibitionBook your stand at the AstraZeneca Conference Centre Here:http://www.elrig.org/bookings//AIRPT13/

PostersBook your stand at the AstraZeneca Conference Centre Here:http://www.elrig.org/bookings//AIRPT13/

In collaboration with:For more information contact: Jackie Howard – [email protected]

Date post:	29-Jul-2020
Category:	Documents
Upload:	others
View:	0 times
Download:	0 times

Manchest onv entre 3r & ept - ELRIG · Thr kly D Williams, Universit er Nov edic oxicity 10.30 –...

Documents